Recently Released Market Study: EGEN, Inc. - Product Pipeline Review - 2012

Recently published research from Global Markets Direct, "EGEN, Inc. - Product Pipeline Review - 2012", is now available at Fast Market Research

Logo

Boston, MA -- (SBWire) -- 11/13/2012 --Global Market Direct's pharmaceuticals report, "EGEN, Inc. - Product Pipeline Review - 2012" provides data on the EGEN, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, EGEN, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from EGEN, Inc. and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- EGEN, Inc. - Brief EGEN, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of EGEN, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of EGEN, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the EGEN, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

View Full Report Details and Table of Contents

Reasons to Get this Report

- Evaluate EGEN, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of EGEN, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the EGEN, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with EGEN, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of EGEN, Inc. and identify potential opportunities in those areas.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Sarcomas - Pipeline Review, H1 2012
- Thrombosis - Pipeline Review, H1 2012
- Inflammatory Bowel Disease - Pipeline Review, H1 2012
- Millennium Pharmaceuticals, Inc. - Product Pipeline Review - 2012
- Depression - Pipeline Review, H1 2012
- Chemotherapy Effects - Pipeline Review, H1 2012
- Chronic Pain - Pipeline Review, H1 2012
- Hepatocellular Carcinoma - Pipeline Review, H1 2012
- Malaria - Pipeline Review, H1 2012
- Heart Failure - Pipeline Review, H1 2012

Media Relations Contact

Bill Thompson
Director of Marketing
800-844-8156
http://www.fastmr.com

View this press release online at: http://rwire.com/179242